Literature DB >> 27432976

HIF2α-arginase axis is essential for the development of pulmonary hypertension.

Andrew S Cowburn1, Alexi Crosby2, David Macias3, Cristina Branco3, Renato D D R Colaço3, Mark Southwood4, Mark Toshner2, Laura E Crotty Alexander5, Nicholas W Morrell2, Edwin R Chilvers2, Randall S Johnson6.   

Abstract

Hypoxic pulmonary vasoconstriction is correlated with pulmonary vascular remodeling. The hypoxia-inducible transcription factors (HIFs) HIF-1α and HIF-2α are known to contribute to the process of hypoxic pulmonary vascular remodeling; however, the specific role of pulmonary endothelial HIF expression in this process, and in the physiological process of vasoconstriction in response to hypoxia, remains unclear. Here we show that pulmonary endothelial HIF-2α is a critical regulator of hypoxia-induced pulmonary arterial hypertension. The rise in right ventricular systolic pressure (RVSP) normally observed following chronic hypoxic exposure was absent in mice with pulmonary endothelial HIF-2α deletion. The RVSP of mice lacking HIF-2α in pulmonary endothelium after exposure to hypoxia was not significantly different from normoxic WT mice and much lower than the RVSP values seen in WT littermate controls and mice with pulmonary endothelial deletion of HIF-1α exposed to hypoxia. Endothelial HIF-2α deletion also protected mice from hypoxia remodeling. Pulmonary endothelial deletion of arginase-1, a downstream target of HIF-2α, likewise attenuated many of the pathophysiological symptoms associated with hypoxic pulmonary hypertension. We propose a mechanism whereby chronic hypoxia enhances HIF-2α stability, which causes increased arginase expression and dysregulates normal vascular NO homeostasis. These data offer new insight into the role of pulmonary endothelial HIF-2α in regulating the pulmonary vascular response to hypoxia.

Entities:  

Keywords:  HIF; hypertension; hypoxia; pulmonary

Mesh:

Substances:

Year:  2016        PMID: 27432976      PMCID: PMC4978263          DOI: 10.1073/pnas.1602978113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis.

Authors:  Christopher J Lettieri; Steven D Nathan; Scott D Barnett; Shahzad Ahmad; Andrew F Shorr
Journal:  Chest       Date:  2006-03       Impact factor: 9.410

2.  Differential activation and antagonistic function of HIF-{alpha} isoforms in macrophages are essential for NO homeostasis.

Authors:  Norihiko Takeda; Ellen L O'Dea; Andrew Doedens; Jung-whan Kim; Alexander Weidemann; Christian Stockmann; Masataka Asagiri; M Celeste Simon; Alexander Hoffmann; Randall S Johnson
Journal:  Genes Dev       Date:  2010-03-01       Impact factor: 11.361

3.  Regulation of human metabolism by hypoxia-inducible factor.

Authors:  Federico Formenti; Dumitru Constantin-Teodosiu; Yaso Emmanuel; Jane Cheeseman; Keith L Dorrington; Lindsay M Edwards; Sandy M Humphreys; Terence R J Lappin; Mary F McMullin; Christopher J McNamara; Wendy Mills; John A Murphy; David F O'Connor; Melanie J Percy; Peter J Ratcliffe; Thomas G Smith; Marilyn Treacy; Keith N Frayn; Paul L Greenhaff; Fredrik Karpe; Kieran Clarke; Peter A Robbins
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

4.  Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy.

Authors:  Reda E Girgis; Hunter C Champion; Gregory B Diette; Roger A Johns; Solbert Permutt; J T Sylvester
Journal:  Am J Respir Crit Care Med       Date:  2005-05-05       Impact factor: 21.405

5.  Nitric oxide and pulmonary arterial pressures in pulmonary hypertension.

Authors:  Roberto F Machado; Medha-Vini Londhe Nerkar; Raed A Dweik; Jeffrey Hammel; Allison Janocha; Jacqueline Pyle; Daniel Laskowski; Constance Jennings; Alejandro C Arroliga; Serpil C Erzurum
Journal:  Free Radic Biol Med       Date:  2004-10-01       Impact factor: 7.376

6.  Pulmonary vascular remodeling correlates with lung eggs and cytokines in murine schistosomiasis.

Authors:  Alexi Crosby; Frances M Jones; Mark Southwood; Susan Stewart; Ralph Schermuly; Ghazwan Butrous; David W Dunne; Nicholas W Morrell
Journal:  Am J Respir Crit Care Med       Date:  2009-12-03       Impact factor: 21.405

7.  Regulation of vascularization by hypoxia-inducible factor 1.

Authors:  Gregg L Semenza
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

8.  Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension.

Authors:  N W Morrell; E N Atochina; K G Morris; S M Danilov; K R Stenmark
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

9.  Endothelial cell HIF-1α and HIF-2α differentially regulate metastatic success.

Authors:  Cristina Branco-Price; Na Zhang; Moritz Schnelle; Colin Evans; Dörthe M Katschinski; Debbie Liao; Lesley Ellies; Randall S Johnson
Journal:  Cancer Cell       Date:  2012-01-17       Impact factor: 31.743

10.  A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter.

Authors:  G Melillo; T Musso; A Sica; L S Taylor; G W Cox; L Varesio
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

View more
  69 in total

Review 1.  Discovery of a murine model of clinical PAH: Mission impossible?

Authors:  Zhiyu Dai; You-Yang Zhao
Journal:  Trends Cardiovasc Med       Date:  2016-12-15       Impact factor: 6.677

2.  Biomechanical Forces and Oxidative Stress: Implications for Pulmonary Vascular Disease.

Authors:  Evgeny A Zemskov; Qing Lu; Wojciech Ornatowski; Christina N Klinger; Ankit A Desai; Emin Maltepe; Jason X-J Yuan; Ting Wang; Jeffrey R Fineman; Stephen M Black
Journal:  Antioxid Redox Signal       Date:  2019-03-19       Impact factor: 8.401

3.  Comprehensive transcriptomic profiling reveals SOX7 as an early regulator of angiogenesis in hypoxic human endothelial cells.

Authors:  Jeff Klomp; James Hyun; Jennifer E Klomp; Kostandin Pajcini; Jalees Rehman; Asrar B Malik
Journal:  J Biol Chem       Date:  2020-02-18       Impact factor: 5.157

Review 4.  Cellular Pathways Promoting Pulmonary Vascular Remodeling by Hypoxia.

Authors:  Larissa A Shimoda
Journal:  Physiology (Bethesda)       Date:  2020-07-01

5.  Endothelial Hypoxia-Inducible Factor-1α Is Required for Vascular Repair and Resolution of Inflammatory Lung Injury through Forkhead Box Protein M1.

Authors:  Xiaojia Huang; Xianming Zhang; David X Zhao; Jun Yin; Guochang Hu; Colin E Evans; You-Yang Zhao
Journal:  Am J Pathol       Date:  2019-05-20       Impact factor: 4.307

6.  Endothelial Hypoxia-Inducible Factor-2α Is Required for the Maintenance of Airway Microvasculature.

Authors:  Xinguo Jiang; Wen Tian; Allen B Tu; Shravani Pasupneti; Eric Shuffle; Petra Dahms; Patrick Zhang; Haoliang Cai; Thanh T Dinh; Bo Liu; Corey Cain; Amato J Giaccia; Eugene C Butcher; M Celeste Simon; Gregg L Semenza; Mark R Nicolls
Journal:  Circulation       Date:  2019-01-22       Impact factor: 29.690

Review 7.  Hypoxia-inducible factor signaling in pulmonary hypertension.

Authors:  Soni Savai Pullamsetti; Argen Mamazhakypov; Norbert Weissmann; Werner Seeger; Rajkumar Savai
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

8.  Polymorphonuclear Leukocytes in Pulmonary Hypertension and Fibrosis: Not Always What They Appear to Be.

Authors:  Nedim Durmus; Gabriele Grunig
Journal:  Am J Respir Cell Mol Biol       Date:  2018-02       Impact factor: 6.914

Review 9.  Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies.

Authors:  Volker H Haase
Journal:  Exp Cell Res       Date:  2017-05-05       Impact factor: 3.905

10.  Exploring New Therapeutic Pathways in Pulmonary Hypertension. Metabolism, Proliferation, and Personalized Medicine.

Authors:  M Patricia George; Mark T Gladwin; Brian B Graham
Journal:  Am J Respir Cell Mol Biol       Date:  2020-09       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.